NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
REHOVOT, Israel, Dec. 5, 2014 (GLOBE NEWSWIRE) — NeuroDerm Ltd. (NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that Oded S. Lieberman, PhD, CEO will present at the Oppenheimer 25th Annual Healthcare Conference on December 10th, 2014 at 8:35am ET in New York. Dr. Lieberman will give a corporate overview and discuss the company’s next-generation treatments for central nervous system disorders, including the company’s flagship product candidates designed to treat moderate to severe Parkinson’s disease. To access a live webcast of this presentation, please visit ir.neuroderm.com/. A replay will be available for one month following the presentation.
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. In Parkinson’s disease, the company has four product candidates which offer a solution for almost every Parkinson’s disease patient from moderate to the very severe stage of the disease. The company has developed a line of levodopa-carbidopa (LD/CD) product candidates administered through a small belt pump that delivers a continuous, controlled dose of LD/CD. The LD/CD line of product candidates includes: ND0612L and ND0612H, delivered subcutaneously, for moderate and for advanced Parkinson’s disease patients, respectively, and ND0680 for a subset of severe Parkinson’s disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD. In addition NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park, Rehovot, Israel.
Oded S. Lieberman, PhD, MBA, CEO
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
Lazar Partners Ltd.
U.S. Media Contact:
Lazar Partners Ltd.